KANCERA AB

Their core work

Kancera AB is a Swedish pharmaceutical SME focused on drug discovery in two therapeutic areas: oncology and neuroinflammation-driven chronic pain. In the cancer space, they work on exploiting synthetic lethal interactions — targeting cancer cells by disabling backup survival pathways — while in the pain and neurodegeneration space, they develop compounds targeting CB2 and CX3CR1 receptors involved in neuroinflammatory signaling. Their H2020 participation was as an industry partner in Marie Skłodowska-Curie training networks, where they hosted and mentored early-stage researchers as part of multi-institutional PhD programmes. This positions them as a bridge between academic drug discovery science and pharmaceutical industry practice.

What they specialise in

How they've shifted over time

Kancera's first H2020 project (SYNTRAIN, 2016) was in pure oncology — specifically the mechanistic exploitation of synthetic lethality in cancer cells — with no documented keyword trail surviving from that period. Their second project (TOBeATPAIN, 2018) shifted focus toward neuroinflammation, chronic pain, peripheral neuropathies, and receptor pharmacology involving cytokines, chemokines, and glial signalling. This represents a meaningful pivot: from cancer cell biology toward CNS and pain indications, possibly reflecting pipeline decisions made around 2017–2018 to expand beyond oncology into the neuroscience space. The two areas are not unrelated — both involve inflammatory signalling and receptor-targeted small molecules — suggesting a coherent underlying platform rather than a random shift.

Kancera appears to be building a dual-focus pipeline — oncology and neuroinflammatory pain — making them a potential partner for consortia that need industry-side receptor pharmacology or translational pain research expertise.

How they like to work

Kancera has participated exclusively as a consortium partner, never as a project coordinator — consistent with a small pharmaceutical SME engaging with academic-led training networks rather than leading them. Their participation in MSCA-ITN consortia typically means they serve as an industry host site for doctoral researchers, contributing proprietary drug discovery know-how and access to compound libraries or assay infrastructure. With 18 unique partners across both projects, their network is broad for a company of their size, though this breadth is partly a structural feature of MSCA training networks rather than purely organic partner selection.

Kancera has collaborated with 18 unique partners across 10 countries, a reach typical of MSCA-ITN consortia that span European academic institutions and industry sites. No geographic concentration is apparent from the available data.

What sets them apart

Kancera occupies an uncommon niche as a Scandinavian biotech SME with simultaneous expertise in oncology (synthetic lethality) and neuroinflammatory pain (CB2/CX3CR1 receptor pharmacology) — two areas that are increasingly converging around shared inflammatory mechanisms. Unlike university groups, they bring industrial drug discovery infrastructure to academic consortia: compound screening, medicinal chemistry, and translational development experience. For consortium builders, they offer the rare combination of SME agility, a live pharmaceutical pipeline, and documented willingness to engage in long-term (4-year) training partnerships rather than short project contributions.

Highlights from their portfolio

• SYNTRAIN
  Kancera's largest H2020 award (EUR 527,319) and their entry into European research networks, centred on synthetic lethality — one of the most commercially significant mechanisms in modern oncology drug discovery.
• TOBeATPAIN
  Signals Kancera's deliberate expansion into the neuroinflammation and chronic pain space, with a specific receptor focus (CB2, CX3CR1) that aligns with a high-value pharmaceutical target class attracting growing industry investment.